Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Gespeichert in:

Autor*in:	Clark, Joseph I [verfasserIn] Morse, Michael A Wong, Michael KK McDermott, David F Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2015

Schlagwörter:	Renal Cell Carcinoma Stable Disease Prospective Cohort Retrospective Cohort Target Therapy

Anmerkung:	© Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (

Übergeordnetes Werk:	Enthalten in: Journal for ImmunoTherapy of Cancer - London : BioMed Central, 2013, 3(2015), Suppl 2 vom: 04. Nov.
Übergeordnetes Werk:	volume:3 ; year:2015 ; number:Suppl 2 ; day:04 ; month:11

Links:	Volltext

DOI / URN:	10.1186/2051-1426-3-S2-P225

Katalog-ID:	SPR036434094

Internformat


LEADER	01000caa a22002652 4500
001	SPR036434094
003	DE-627
005	20230519192136.0
007	cr uuu---uuuuu
008	201007s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/2051-1426-3-S2-P225 \|2 doi
035			\|a (DE-627)SPR036434094
035			\|a (SPR)2051-1426-3-S2-P225-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Clark, Joseph I \|e verfasserin \|4 aut
245	1	0	\|a Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
650		4	\|a Renal Cell Carcinoma \|7 (dpeaa)DE-He213
650		4	\|a Stable Disease \|7 (dpeaa)DE-He213
650		4	\|a Prospective Cohort \|7 (dpeaa)DE-He213
650		4	\|a Retrospective Cohort \|7 (dpeaa)DE-He213
650		4	\|a Target Therapy \|7 (dpeaa)DE-He213
700	1		\|a Morse, Michael A \|4 aut
700	1		\|a Wong, Michael KK \|4 aut
700	1		\|a McDermott, David F \|4 aut
700	1		\|a Kaufman, Howard L \|4 aut
700	1		\|a Daniels, Gregory A \|4 aut
700	1		\|a Perritt, Jessica C \|4 aut
700	1		\|a Hua, Hong \|4 aut
700	1		\|a Aung, Sandra \|4 aut
773	0	8	\|i Enthalten in \|t Journal for ImmunoTherapy of Cancer \|d London : BioMed Central, 2013 \|g 3(2015), Suppl 2 vom: 04. Nov. \|w (DE-627)750086335 \|w (DE-600)2719863-7 \|x 2051-1426 \|7 nnns
773	1	8	\|g volume:3 \|g year:2015 \|g number:Suppl 2 \|g day:04 \|g month:11
856	4	0	\|u https://dx.doi.org/10.1186/2051-1426-3-S2-P225 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 3 \|j 2015 \|e Suppl 2 \|b 04 \|c 11

Indexfelder

author_variant	j i c ji jic m a m ma mam m k w mk mkw d f m df dfm h l k hl hlk g a d ga gad j c p jc jcp h h hh s a sa
matchkey_str	article:20511426:2015----::uaiiyfepneiptetwtmtsairnlelacnmtetdi
hierarchy_sort_str	2015
publishDate	2015
allfields	10.1186/2051-1426-3-S2-P225 doi (DE-627)SPR036434094 (SPR)2051-1426-3-S2-P225-e DE-627 ger DE-627 rakwb eng Clark, Joseph I verfasserin aut Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( Renal Cell Carcinoma (dpeaa)DE-He213 Stable Disease (dpeaa)DE-He213 Prospective Cohort (dpeaa)DE-He213 Retrospective Cohort (dpeaa)DE-He213 Target Therapy (dpeaa)DE-He213 Morse, Michael A aut Wong, Michael KK aut McDermott, David F aut Kaufman, Howard L aut Daniels, Gregory A aut Perritt, Jessica C aut Hua, Hong aut Aung, Sandra aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 3(2015), Suppl 2 vom: 04. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:3 year:2015 number:Suppl 2 day:04 month:11 https://dx.doi.org/10.1186/2051-1426-3-S2-P225 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2015 Suppl 2 04 11
spelling	10.1186/2051-1426-3-S2-P225 doi (DE-627)SPR036434094 (SPR)2051-1426-3-S2-P225-e DE-627 ger DE-627 rakwb eng Clark, Joseph I verfasserin aut Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( Renal Cell Carcinoma (dpeaa)DE-He213 Stable Disease (dpeaa)DE-He213 Prospective Cohort (dpeaa)DE-He213 Retrospective Cohort (dpeaa)DE-He213 Target Therapy (dpeaa)DE-He213 Morse, Michael A aut Wong, Michael KK aut McDermott, David F aut Kaufman, Howard L aut Daniels, Gregory A aut Perritt, Jessica C aut Hua, Hong aut Aung, Sandra aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 3(2015), Suppl 2 vom: 04. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:3 year:2015 number:Suppl 2 day:04 month:11 https://dx.doi.org/10.1186/2051-1426-3-S2-P225 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2015 Suppl 2 04 11
allfields_unstemmed	10.1186/2051-1426-3-S2-P225 doi (DE-627)SPR036434094 (SPR)2051-1426-3-S2-P225-e DE-627 ger DE-627 rakwb eng Clark, Joseph I verfasserin aut Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( Renal Cell Carcinoma (dpeaa)DE-He213 Stable Disease (dpeaa)DE-He213 Prospective Cohort (dpeaa)DE-He213 Retrospective Cohort (dpeaa)DE-He213 Target Therapy (dpeaa)DE-He213 Morse, Michael A aut Wong, Michael KK aut McDermott, David F aut Kaufman, Howard L aut Daniels, Gregory A aut Perritt, Jessica C aut Hua, Hong aut Aung, Sandra aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 3(2015), Suppl 2 vom: 04. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:3 year:2015 number:Suppl 2 day:04 month:11 https://dx.doi.org/10.1186/2051-1426-3-S2-P225 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2015 Suppl 2 04 11
allfieldsGer	10.1186/2051-1426-3-S2-P225 doi (DE-627)SPR036434094 (SPR)2051-1426-3-S2-P225-e DE-627 ger DE-627 rakwb eng Clark, Joseph I verfasserin aut Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( Renal Cell Carcinoma (dpeaa)DE-He213 Stable Disease (dpeaa)DE-He213 Prospective Cohort (dpeaa)DE-He213 Retrospective Cohort (dpeaa)DE-He213 Target Therapy (dpeaa)DE-He213 Morse, Michael A aut Wong, Michael KK aut McDermott, David F aut Kaufman, Howard L aut Daniels, Gregory A aut Perritt, Jessica C aut Hua, Hong aut Aung, Sandra aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 3(2015), Suppl 2 vom: 04. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:3 year:2015 number:Suppl 2 day:04 month:11 https://dx.doi.org/10.1186/2051-1426-3-S2-P225 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2015 Suppl 2 04 11
allfieldsSound	10.1186/2051-1426-3-S2-P225 doi (DE-627)SPR036434094 (SPR)2051-1426-3-S2-P225-e DE-627 ger DE-627 rakwb eng Clark, Joseph I verfasserin aut Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( Renal Cell Carcinoma (dpeaa)DE-He213 Stable Disease (dpeaa)DE-He213 Prospective Cohort (dpeaa)DE-He213 Retrospective Cohort (dpeaa)DE-He213 Target Therapy (dpeaa)DE-He213 Morse, Michael A aut Wong, Michael KK aut McDermott, David F aut Kaufman, Howard L aut Daniels, Gregory A aut Perritt, Jessica C aut Hua, Hong aut Aung, Sandra aut Enthalten in Journal for ImmunoTherapy of Cancer London : BioMed Central, 2013 3(2015), Suppl 2 vom: 04. Nov. (DE-627)750086335 (DE-600)2719863-7 2051-1426 nnns volume:3 year:2015 number:Suppl 2 day:04 month:11 https://dx.doi.org/10.1186/2051-1426-3-S2-P225 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2015 Suppl 2 04 11
language	English
source	Enthalten in Journal for ImmunoTherapy of Cancer 3(2015), Suppl 2 vom: 04. Nov. volume:3 year:2015 number:Suppl 2 day:04 month:11
sourceStr	Enthalten in Journal for ImmunoTherapy of Cancer 3(2015), Suppl 2 vom: 04. Nov. volume:3 year:2015 number:Suppl 2 day:04 month:11
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Renal Cell Carcinoma Stable Disease Prospective Cohort Retrospective Cohort Target Therapy
isfreeaccess_bool	false
container_title	Journal for ImmunoTherapy of Cancer
authorswithroles_txt_mv	Clark, Joseph I @@aut@@ Morse, Michael A @@aut@@ Wong, Michael KK @@aut@@ McDermott, David F @@aut@@ Kaufman, Howard L @@aut@@ Daniels, Gregory A @@aut@@ Perritt, Jessica C @@aut@@ Hua, Hong @@aut@@ Aung, Sandra @@aut@@
publishDateDaySort_date	2015-11-04T00:00:00Z
hierarchy_top_id	750086335
id	SPR036434094
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036434094</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519192136.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/2051-1426-3-S2-P225</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036434094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)2051-1426-3-S2-P225-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clark, Joseph I</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Renal Cell Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stable Disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prospective Cohort</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retrospective Cohort</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Target Therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morse, Michael A</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong, Michael KK</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McDermott, David F</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaufman, Howard L</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Daniels, Gregory A</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perritt, Jessica C</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hua, Hong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aung, Sandra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal for ImmunoTherapy of Cancer</subfield><subfield code="d">London : BioMed Central, 2013</subfield><subfield code="g">3(2015), Suppl 2 vom: 04. Nov.</subfield><subfield code="w">(DE-627)750086335</subfield><subfield code="w">(DE-600)2719863-7</subfield><subfield code="x">2051-1426</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">day:04</subfield><subfield code="g">month:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/2051-1426-3-S2-P225</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2015</subfield><subfield code="e">Suppl 2</subfield><subfield code="b">04</subfield><subfield code="c">11</subfield></datafield></record></collection>
author	Clark, Joseph I
spellingShingle	Clark, Joseph I misc Renal Cell Carcinoma misc Stable Disease misc Prospective Cohort misc Retrospective Cohort misc Target Therapy Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
authorStr	Clark, Joseph I
ppnlink_with_tag_str_mv	@@773@@(DE-627)750086335
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2051-1426
topic_title	Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) Renal Cell Carcinoma (dpeaa)DE-He213 Stable Disease (dpeaa)DE-He213 Prospective Cohort (dpeaa)DE-He213 Retrospective Cohort (dpeaa)DE-He213 Target Therapy (dpeaa)DE-He213
topic	misc Renal Cell Carcinoma misc Stable Disease misc Prospective Cohort misc Retrospective Cohort misc Target Therapy
topic_unstemmed	misc Renal Cell Carcinoma misc Stable Disease misc Prospective Cohort misc Retrospective Cohort misc Target Therapy
topic_browse	misc Renal Cell Carcinoma misc Stable Disease misc Prospective Cohort misc Retrospective Cohort misc Target Therapy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal for ImmunoTherapy of Cancer
hierarchy_parent_id	750086335
hierarchy_top_title	Journal for ImmunoTherapy of Cancer
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)750086335 (DE-600)2719863-7
title	Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
ctrlnum	(DE-627)SPR036434094 (SPR)2051-1426-3-S2-P225-e
title_full	Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
author_sort	Clark, Joseph I
journal	Journal for ImmunoTherapy of Cancer
journalStr	Journal for ImmunoTherapy of Cancer
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
author_browse	Clark, Joseph I Morse, Michael A Wong, Michael KK McDermott, David F Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra
container_volume	3
format_se	Elektronische Aufsätze
author-letter	Clark, Joseph I
doi_str_mv	10.1186/2051-1426-3-S2-P225
title_sort	durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (hd il-2)
title_auth	Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
abstract	© Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
abstractGer	© Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
abstract_unstemmed	© Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	Suppl 2
title_short	Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
url	https://dx.doi.org/10.1186/2051-1426-3-S2-P225
remote_bool	true
author2	Morse, Michael A Wong, Michael KK McDermott, David F Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra
author2Str	Morse, Michael A Wong, Michael KK McDermott, David F Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra
ppnlink	750086335
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1186/2051-1426-3-S2-P225
up_date	2024-07-03T17:35:05.280Z
_version_	1803580190526275584
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036434094</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519192136.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/2051-1426-3-S2-P225</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036434094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)2051-1426-3-S2-P225-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clark, Joseph I</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Clark et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Renal Cell Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stable Disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prospective Cohort</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retrospective Cohort</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Target Therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morse, Michael A</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong, Michael KK</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McDermott, David F</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaufman, Howard L</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Daniels, Gregory A</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perritt, Jessica C</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hua, Hong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aung, Sandra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal for ImmunoTherapy of Cancer</subfield><subfield code="d">London : BioMed Central, 2013</subfield><subfield code="g">3(2015), Suppl 2 vom: 04. Nov.</subfield><subfield code="w">(DE-627)750086335</subfield><subfield code="w">(DE-600)2719863-7</subfield><subfield code="x">2051-1426</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">day:04</subfield><subfield code="g">month:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/2051-1426-3-S2-P225</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2015</subfield><subfield code="e">Suppl 2</subfield><subfield code="b">04</subfield><subfield code="c">11</subfield></datafield></record></collection>
score	7.3998156

Nicht das Richtige dabei?

Schreiben Sie uns!

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?